An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

 
• By Jessica Merrill and Mandy Jackson
ReviewStamp_1200x675
Amarin's Vascepa will get a US FDA advisory committee review. • Source: Shutterstock

More from Cardiovascular

More from Therapeutic Category